You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR SEMAXANIB


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Semaxanib

Trial ID Title Status Sponsor Phase Summary
NCT00003720 ↗ SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed Pfizer Phase 1 RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
NCT00004252 ↗ Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Completed Pfizer Phase 3 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known whether chemotherapy is more effective with or without SU5416 in treating metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of leucovorin and fluorouracil with or without SU5416 in treating patients who have metastatic colorectal cancer.
NCT00004868 ↗ SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy Completed National Cancer Institute (NCI) Phase 1/Phase 2 RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.
NCT00004868 ↗ SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy Completed North American Brain Tumor Consortium Phase 1/Phase 2 RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.
NCT00004868 ↗ SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1/Phase 2 RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.
NCT00005042 ↗ SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed National Cancer Institute (NCI) Phase 2 RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Semaxanib

Condition Name

Condition Name for
Intervention Trials
Sarcoma 5
Unspecified Adult Solid Tumor, Protocol Specific 4
Colorectal Cancer 3
Head and Neck Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Sarcoma 5
Colorectal Neoplasms 3
Central Nervous System Neoplasms 2
Sarcoma, Kaposi 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Semaxanib

Trials by Country

Trials by Country for
Location Trials
United States 147
Canada 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 11
Texas 9
Illinois 7
New York 7
Ohio 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Semaxanib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 2
Phase 2 12
Phase 1/Phase 2 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 21
Terminated 4
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Semaxanib

Sponsor Name

Sponsor Name for
Sponsor Trials
National Cancer Institute (NCI) 25
Case Comprehensive Cancer Center 3
Jonsson Comprehensive Cancer Center 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
NIH 25
Other 18
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.